



NOTICE OF PROPOSED RULEMAKING

INCLUDING STATEMENT OF NEED & FISCAL IMPACT

CHAPTER 855

BOARD OF PHARMACY

FILED: 10/09/2026 2:18 PM

ARCHIVES DIVISION SECRETARY OF STATE

FILING CAPTION: Prescribing Pursuant to Protocol; COVID-19, Influenza, RSV vaccine Protocols and Standard Vaccination Protocols

LAST DAY AND TIME TO OFFER COMMENT TO AGENCY: 11/24/2026 4:30 PM

The Agency requests public comment on whether other options should be considered for achieving the rule's substantive goals while reducing negative economic impact of the rule on business.

CONTACT:

Rachel Melvin
971-673-0001
pharmacy.rulemaking@bop.oregon.gov
800 NE Oregon St., Suite 150
Portland, OR 97232

Filed By:

Rachel Melvin
Rules Coordinator

HEARING(S)

Auxiliary aids for persons with disabilities are available upon advance request. Notify the contact listed above.

DATE: 11/24/2026

TIME: 9:30 AM

OFFICER: Rachel Melvin

REMOTE HEARING DETAILS

MEETING URL: [Click here to join the meeting](#)

PHONE NUMBER: 503-446-4951

CONFERENCE ID: 538650615

SPECIAL INSTRUCTIONS:

This hearing will be held virtually via Microsoft Teams.

If you wish to present oral testimony virtually during this hearing, sign up on our website at

www.oregon.gov/pharmacy/pages/rulemaking-information or email your first and last name and email address to pharmacy.rulemaking@bop.oregon.gov. Please indicate which rule(s) you would like to comment on.

You must submit written comments before 4:30PM on November 24, 2026. Email written comments to pharmacy.rulemaking@bop.oregon.gov.

NEED FOR THE RULE(S):

Amends rule by adopting new versions of the of the COVID-19, Influenza, and Respiratory Syncytial Virus (RSV) vaccine protocols and Standard Vaccination Protocols for Adults 18 yrs and older and 7-17 years of age and Managing Adverse Reactions.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE:

Special 9/18/2026 Public Health & Pharmacy Formulary Advisory Committee meeting materials
https://www.oregon.gov/pharmacy/Documents/Special_PHPFAC_9.18.2026_Agenda.pdf

STATEMENT IDENTIFYING HOW ADOPTION OF RULE(S) WILL AFFECT RACIAL EQUITY IN THIS STATE:

The proposed rule amendments may increase Oregonians access to vaccines.

FISCAL AND ECONOMIC IMPACT:

No fiscal anticipated. Licensees, registrants and interested parties will have an opportunity to provide fiscal and economic impact statements during the open comment period.

COST OF COMPLIANCE:

(1) Identify any state agencies, units of local government, and members of the public likely to be economically affected by the rule(s). (2) Effect on Small Businesses: (a) Estimate the number and type of small businesses subject to the rule(s); (b) Describe the expected reporting, recordkeeping and administrative activities and cost required to comply with the rule(s); (c) Estimate the cost of professional services, equipment supplies, labor and increased administration required to comply with the rule(s).

The proposed rule amendments will have no additional economic impact on state agencies, units of local government, the public or licensees or registrants who identify as a small business.

DESCRIBE HOW SMALL BUSINESSES WERE INVOLVED IN THE DEVELOPMENT OF THESE RULE(S):

Registrants who identify as a small business and who have signed up to receive notices will receive an email notice of proposed rulemaking via GovDelivery and will have an opportunity to provide public comment on the proposed rules and protocols.

WAS AN ADMINISTRATIVE RULE ADVISORY COMMITTEE CONSULTED? NO IF NOT, WHY NOT?

No. Subject Matter Experts (SME) are responsible for drafting proposed vaccine protocol amendments and the Public Health and Pharmacy Formulary Advisory Committee (PHPFAC) is responsible for recommending proposed protocols to the board for consideration.

AMEND: 855-115-0345

RULE SUMMARY: Amends 4(a)(b)(c) by amending Step 4 on the assessment and treatment care pathway for both the Standard Vaccination Protocol for adults 18 years and older and the Standard Vaccination Protocol for persons 7-17 years of age. Amends Standard Vaccination Protocol for Managing Adverse Reactions by revising Table 1, Table 2, Table 3, corrects rule reference, amends broken links, adds new links to the references section and incorporates existing Appendix A, B and C. Amends (5)(a) by adding a new version of the COVID-19 vaccine protocol, amends (5)(b) by adding a new version of the Influenza vaccine protocol and amends (5)(c) by adding a new version of the Respiratory Syncytial Virus protocol as recommended by the Public Health and Pharmacy Formulary Advisory Committee.

CHANGES TO RULE:

855-115-0345

Services: Prescribing Pursuant to - Protocol

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices pursuant to a Protocol. Protocols in their entirety are adopted by the board by this rule pursuant to the respective effective date referenced and can be found on the board website at <https://www.oregon.gov/pharmacy/Pages/PFAC.aspx>. Pharmacists can prescribe pursuant to the protocols listed below.¶¶

(1) Continuation of Therapy Protocol including emergency refills of insulin (v. 02/2026).¶¶

(2) Conditions Protocols:¶¶

(a) Cough and cold symptom management:¶¶

(A) Benzonatate (v. 06/2021);¶¶

(B) Short-acting beta agonists (v. 06/2021);¶¶

(C) Intranasal corticosteroids (v. 06/2021);¶¶

(b) COVID-19 Antigen Self-Test (v. 12/2021);¶¶

(c) SARS-CoV-2 Antiviral (v. 08/2024).¶¶

(3) Preventative Care Protocols:¶¶

(a) Emergency Contraception (v. 06/2021);¶¶

(b) Male and female condoms (v. 06/2021);¶¶

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2024);¶¶

(d) Travel Medications (v. 06/2024);¶¶

(e) HIV Post-exposure Prophylaxis (PEP) (v. 01/2026);¶¶

(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 01/2026); ¶¶

(g) Contraception (v. 06/2025);¶¶

(h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024);¶¶

(i) Short-acting Opioid Antagonists (v. 06/2024); ¶¶

(j) Medications for Opioid Use Disorder - Initiation of Care (v. 02/2026); and¶¶

(k) Medications for Opioid Use Disorder - Continuation/Modification of Care (v. 02/2026). ¶¶

(4) Vaccine Protocols:¶¶

(a) Vaccination Protocol for Adults 18 Years of Age and Older (v. 04~~2~~9/2026);¶¶

(b) Vaccination Protocol for Ages 7 through 17 Years (v. 04~~2~~9/2026); and¶¶

(c) Vaccination Protocol for Managing Adverse Reactions (v. 08~~2~~9/2025~~6~~).¶¶

(5) Board Excluded Vaccine Protocols:¶¶

(a) Coronavirus 19 (v. 04~~2~~9/2026);¶¶

(b) Influenza (v. 04~~2~~9/2026); and¶¶

(c) Respiratory Syncytial Virus (v. 09/2025~~6~~). ¶¶

[Publications: Publications referenced are available from the agency.]

Statutory/Other Authority: ORS 689.205, ORS 689.005, ORS 689.698

Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689, ORS 689.005, ORS 689.698